Read the latest press releases from Calliditas Therapeutics by clicking on a title below.

For press enquiries please contact us.

Calliditas Therapeutics granted orphan drug designation by the FDA for Primary biliary cholangitis

Year-end report, 2018

Calliditas Therapeutics granted orphan drug designation by the FDA for Autoimmune hepatitis

Calliditas Therapeutics AB
Wallingatan 26B
SE-111 24 Stockholm
Sweden

Company number: 556659-9766

© Calliditas Therapeutics AB 2019